Clinical Trial Update: Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Thymoglobulin, Campath-1H, and Daclizumab in adult living-donor kidney transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Living-donor Kidney Transplantation

Drugs mentioned

• Campath-1H (alemtuzumab)
• Daclizumab (daclizumab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University of Miami | Conditions: Living-Donor Kidney Transplant | Phase 4 | Status: COMPLETED